Dexter Star Michael Hall Battles Lymphoma

Michael Hall, an actor who has played a role on a number of TV shows including Six Feet Under and Dexter has reportedly been battling cancer. He announced the news yesterday, but did not say when he was diagnosed.

"I feel fortunate to have been diagnosed with an imminently treatable and curable condition, and I thank my doctors and nurses for their expertise and care," Hall, 38, said Wednesday in a statement. His medical team is based in the Los Angeles area.

His spokesman, Craig Bankey, said Hall’s cancer is in remission but the actor will continue scheduled treatments.

Mr. Hall and his wife "Dexter" costar Jennifer Carpenter plan to attend Sunday's Golden Globes as Hall's dominated for the best dramatic actor and the show as the best drama. He is nominated for his role as Dexter Morgan, a serial killer working with the police.

He also plans to attend the Screen Actors Guild Awards the following Saturday, where Hall and the cast are also nominated. He will return to shooting the fifth season of Dexter later this year.

His father died of cancer when Hall was eleven years old.

Sending many good wishes and healing prayers your way.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap